Wednesday, March 25, 2020 9:03:38 AM
Currently, the main Covid-19 detection method is nucleic acid detection. The average detection takes 5-6 hours, while the misdetection rate is high and the cost is high. In the past two months, the Company has been dedicated to developing a more efficient and affordable testing kit for Covid-19 through its biochemical laboratory that the Company jointly established with School of Bioscience and Engineering, Fuzhou University.
The Company made a breakthrough and successfully developed the colloidal gold testing kit by adopting the antibody detection method. The colloidal gold testing kits innovatively use multiple target tests combined with IgM / IgG tests, which greatly improve the detection sensitivity. The detection rate of IgM antibody in clinical patients is more than 70%, and that of IgG antibody in convalescent patients is more than 90%. The testing kits not only greatly improve the success rate of detection, but also greatly shorten the detection time to 10-15 minutes, while the cost is relatively low compared to the nucleic acid detection.
"We are ready to submit the CFDA certification application next week, and we expect to receive the approval soon since the CFDA has granted emergency approval mechanism for Covid-19 Testing Kits. We also plan to apply for CE certification in Europe and FDA certification in the United States. We are very grateful to the experts of Fuzhou University and the staff of our biochemical laboratory for their hard work. At present, the company has begun to transform the production workshop to prepare for mass production. We believe that through the efforts of companies like us, people all over the world will be able to use more efficient and affordable Covid-19 testing kits in the near future." Mr. Xuezhu Wang, CEO of the Company, proudly stated.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
New York Yankees and Duke Basketball
Recent HAPP News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/03/2024 08:15:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/14/2024 09:00:15 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM